Life Science Lunch - The Supreme Court Ruling on Gene Patentability: How the Myriad Genetics Ruling Affects the Future of Biotechnology
What: Life Sciences Lunch Series - "The Supreme Court Ruling on Gene Patentability: How the Myriad Genetics Ruling Affects the Future of Biotechnology"
When: July 16, 2013 | 11:30 a.m. (ET) Registration and Lunch | 12:00 p.m. to 1:00 p.m. (ET) Presentation - Adjournment will be on time
Program Description: While the Supreme Court's decision offers urgently-needed certainty for research-driven companies that rely on cDNA patents for investment in innovation, it could also unnecessarily create business uncertainty for a broader range of biotechnology inventions. At least 8,000 currently existing patents will be affected by this decision and the companies who will be most likely impacted are small operations who rely upon the strength of their intellectual property to secure funding for additional research. How murky is the path ahead and what strategies should you be considering to keep your plans on track?
Hans Sauer, Deputy General Counsel, Intellectual Property, BIO
Eric E. Williams, Pharm.D., Associate, Intellectual Property, Barnes & Thornburg LLP
Live location: Barnes & Thornburg LLP | 5th Floor Auditorium | 11 South Meridian Street, Indianapolis, IN
Note: This event will be broadcast to other Barnes & Thornburg offices in Elkhart, South Bend and Fort Wayne, Ind.; sometimes available in Barnes & Thornburg offices in Chicago; Grand Rapids; Washington, D.C.; Atlanta; Minneapolis; Columbus, Ohio; and Los Angeles. Also cooperating facilities in Hammond, Merrillville, New Albany, Richmond, and West Lafayette.